DE SB34 | 2019-2020 | 150th General Assembly


Completed Legislative Action
Spectrum: Moderate Partisan Bill (Democrat 19-3)
Status: Passed on June 12 2019 - 100% progression
Action: 2019-06-12 - Signed by Governor
Text: Latest bill text (Engrossed) [HTML]


This Act creates a Prescription Opioid Impact Fund (Fund) through a prescription opioid impact fee (Fee) that is paid by pharmaceutical manufacturer. The anticipated revenue from the Fee is $2.8 million in 2020, $2.7 million in 2021, and $2.5 million in 2022.:

Tracking Information

Register now for our free OneVote public service or GAITS Professional trial account and you can begin tracking this and other legislation, all driven by the real-time data of the LegiScan API. Providing tools allowing you to research pending legislation, stay informed with email alerts, content feeds, and share dynamic reports. Use our new PolitiCorps to join with friends and collegaues to monitor & discuss bills through the process.

Monitor Legislation or view this same bill number from multiple sessions or take advantage of our national legislative search.


An Act To Amend Title 16 Of The Delaware Code Creating A Prescription Opioid Impact Fund.


Roll Calls

2019-05-16 - House - House Third Reading (Y: 33 N: 8 NV: 0 Abs: 0) [PASS]
2019-04-09 - Senate - Senate Third Reading (Y: 17 N: 4 NV: 0 Abs: 0) [PASS]


2019-06-12 Signed by Governor
2019-05-16 Passed By House. Votes: 33 YES 8 NO
2019-05-08 Reported Out of Committee (Health & Human Development) in House with 1 Favorable, 6 On Its Merits
2019-04-11 Assigned to Health & Human Development Committee in House
2019-04-09 Passed By Senate. Votes: 17 YES 4 NO
2019-04-09 Amendment SA 1 to SB 34 - Passed By Senate. Votes: 19 YES 2 NO
2019-03-27 Reported Out of Committee (Health & Social Services) in Senate with 1 Favorable, 3 On Its Merits
2019-03-12 Introduced and Assigned to Health & Social Services Committee in Senate

Delaware State Sources

Bill Comments